IA
CCCC icon

IFP Advisors’s C4 Therapeutics CCCC Stock Holding History

IFP Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17
Closed -$38 – 4904
2025
Q3 		$38 Sell
17
-17
-50% -$41 ﹤0.01% 4689
2025
Q2 		$48 Buy
+34
New +$49 ﹤0.01% 4803

Other funds holding CCCC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

IFP Advisors's CCCC Position: Q4 2025 in Review

IFP Advisors sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 17 shares — an estimated $38 sold.

IFP Advisors first reported a position in CCCC in Q2 2025 and held it in 2 quarters. The position peaked at $48 in Q2 2025. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

  • IFP Advisors reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
  • IFP Advisors sold 17 C4 Therapeutics shares in Q4 2025, an estimated $38.
  • IFP Advisors first reported a position in C4 Therapeutics in Q2 2025 and held it in 2 quarters.
  • IFP Advisors's C4 Therapeutics position peaked at $48 in Q2 2025.
  • 101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.